Investors

2026 Q2 Results

Recent Releases

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark  Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada GAITHERSBURG, Md., Aug.

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict,

Recent Events

08/05/26 08/05/26 5:00 PM EDT Wednesday, August 5, 2026 5:00 PM EDT

04/30/26 04/30/26 5:00 PM EDT Thursday, April 30, 2026 5:00 PM EDT

Woman in Lab

Email Alerts Subscription

Receive email alerts whenever Emergent posts new information.

Sign Up

2025 Annual Report

2026 Proxy Statement

2025 ESG Report

IR Contact

Rich Lindahl
Executive Vice President, Chief Financial Officer
Emergent BioSolutions Inc.
Phone: (240) 631-3360
lindahlr@ebsi.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
Toll Free: 877-830-4936
International: 720-378-5591
Website: shareholder.broadridge.com

X